https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2022-04-26 07:20:272022-04-26 07:20:27Futura Medical Full Year Results for the year ended 31 December 2021
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2022-04-21 17:24:512022-04-21 17:24:51Novo Growth – 2021, A Year in Review
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2022-04-21 08:17:352022-04-21 08:17:35Biocomposites wins two Queen’s Awards for Enterprise in Innovation and International Trade
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2022-04-20 08:51:562022-04-20 08:51:56Leading inhalation APIs expert Inke to triple production capacity
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2022-04-14 10:17:422022-04-14 10:17:42ISA Pharmaceuticals announces the start of clinical trial using its novel AMPLIVANT® technology
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2022-04-12 10:56:372022-04-12 10:56:37Destiny Pharma – Audited results for the year ended 31 December 2021
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2022-04-12 08:08:422022-04-12 08:08:42Biocomposites to present data on STIMULAN® and genex® at ECCMID 2022
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2022-04-11 17:32:242022-09-30 10:15:31Adcendo – Data Presentation on uPARAP targeting ADCs in Osteosarcoma PDX Models at the 2022 AACR Annual Meeting
https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos.png
180
300
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2022-04-11 09:00:542023-06-14 15:52:40Optimum Hires Nick Bastin Further Strengthening Leadership Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2022-04-07 14:12:552022-04-07 14:12:55Novo Holdings Portfolio Company ReViral to be Acquired by Pfizer
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2022-04-05 09:09:352022-04-05 09:09:35eTheRNA Announces Relocation and Expansion of R&D Facility
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2022-04-01 13:14:292022-09-30 10:16:19Asceneuron Publishes Pioneering Preclinical Efficacy Data on its Novel Clinical Molecule ASN90 in Both Alzheimer’s and Parkinson’s Disease Models
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2022-03-30 10:57:312022-03-30 10:57:31Novo Holdings’ Principal Investments Provides Update on a Record Year
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2022-03-30 09:19:222022-03-30 09:19:22Bionical Emas: Ian Fraser appointed as Executive Vice President, Clinical Development.
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2022-03-30 08:04:162022-03-30 08:04:16Invizius Awarded Major Biomedical Catalyst Grant to bring Anti-Inflammatory Haemodialysis Treatment to The Clinic
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2022-03-29 12:14:192022-03-29 12:14:19Novo Holdings and HealthQuad invest in Qure.ai
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2022-03-29 11:55:592022-03-29 11:55:59Rejuvenate Biomed Started a Groundbreaking Clinical Trial and Expands for Future Growth
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2022-03-29 11:53:242022-03-29 11:53:24eTheRNA Manufacturing Announces New LNP Formulation Development and Production Service
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2022-03-28 14:37:422022-03-28 14:37:42EXACT Therapeutics Announces Appointment of Dr Per Walday as Chief Executive Officer
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2022-03-28 11:25:432022-03-28 11:25:43DelSiTech Enters into an Exclusive Licensing Agreement with Optifye Therapeutics for the Development of a Controlled Release Ophthalmic Eye Drop ProductFor more information about Optimum Strategic Communications, please get in touch.
